Laurus Labs Ltd

Net profit of Laurus Labs rose 882.71% to Rs 194.97 crore in the quarter ended September 2025 as against Rs 19.84 crore during the previous quarter ended September 2024. Sales rose 35.12% to Rs 1653.47 crore in the quarter ended September 2025 as against Rs 1223.70 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales1653.471223.70 35 OPM %24.3914.57 - PBDT390.22130.32 199 PBT269.7322.81 1083 NP194.9719.84 883 Powered by Capital Market - Live

Profit before tax (PBT) jumped to Rs 269.73 crore in Q2 FY26 compared with Rs 22.81 crore in Q2 FY25, reflecting over elevenfold growth. Total expenses increased 17.02% to Rs 1,410.70 crore in Q2 FY26, compared with Rs 1,205.49 crore in Q2 FY25. Cost of material consumed stood at Rs 676.75 crore (up 17.25% YoY), employee benefit expense was at Rs 215.56 crore (up 20.61% YoY) while finance cost stood at Rs 40 crore (down 23.97% YoY) during the period under review. EBITDA surged 136% to Rs 429 crore in Q2 FY26, compared with Rs 182 crore in Q2 FY25. EBITDA margin improved to 26% in Q2 FY26 as against 14.9% recorded in Q2 FY25. Revenue from CDMO jumped 53% to Rs 518 crore in Q2 FY26, compared with Rs 339 crore in Q2 FY25. Revenue from small molecules increased 58% YoY to Rs 471 crore in Q2 FY26, driven by several late phase and commercial deliveries. Revenue from Bio business stood at Rs 47 crore, up 18% YoY. Revenue from Generics rose 28% to Rs 1,135 crore in Q2 FY26 compared with Rs 885 crore in Q2 FY25, primarily driven by continued uptake in ARV volumes, further supported by developed market supplies. Revenue from API increased 11% YoY to Rs 617 crore in Q2 FY26. Revenue from Finished Dosages Form (FDF) business climbed 58% YoY to Rs 518 crore in Q2 FY26. On half-yearly basis, the company's consolidated net profit skyrocketed to Rs 354.83 crore in Q2 FY26 compared with Rs 29.93 crore posted in same quarter last year. Revenue from operations jumped 33.26% YoY to Rs 3,223.04 crore in Q2 FY26. Satyanarayana Chava, founder 'We continue to maintain leadership position in ARVs and make encouraging progress in delivering important clinical and commercial programs. Our Q2 reflects on-going expansion of CDMO business, supported by sustained growth in Generics. Earlier this quarter we announced land allocation from Andhra government and proposed investments to support future business expansion, augmenting our offerings across manufacturing scale and new technologies. We also made strategic investment of US$ 2mn in Aarvik Therapeutics to have access to novel Antibody-drug conjugates (ADC) technology and pipeline aimed at accelerating our integrated ADC services. V V Ravi Kumar, executive director & chief financial officer, said, 'Our strong Q2 performance was in line with expectations. We are pleased to report that fundamentals of our business remain strong, with sustained growth momentum in CDMO and Generic business. We have achieved revenues of Rs 1,653 crore, representing 35% growth and EBITDA of Rs 429 crore, representing 136% growth. The EBITDA margins continue to remain very healthy at 26.0%, supported by continuing operating leverage Overall, we reported strong H1 performance. We achieved Rs 3,223 crore in revenues, representing 33% growth and EBITDA of Rs 818 crore, representing 132% growth, resulting in 25.4% EBITDA margins marking over 10% pts improvement over last year. Gross margins improved by over 4.5% pts to 59.6% due to favorable CDMO mix and operational improvements. Net Debt leverage has decreased significantly over last year to 1.3x EBITDA despite continuing CAPEX investments. Going ahead, we retain our focus to invest behind high value CDMO/CMO business opportunities to drive near and long-term growth and returns for our shareholders.' Meanwhile, the company's board declared a interim dividend of Rs 0.80 per share with face value of Rs 2 each for FY26. The record date for the dividend is fixed as 31 October 2025, and the payment will be made on or after 12 November 2025. Laurus Labs is a research-driven pharmaceutical and biotechnology company. It develops and manufactures select Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF) across anti-retroviral, oncology, cardiovascular, and gastro therapeutics. It offers end-to-end CDMO services, supporting innovators from early-stage development to commercial production.Powered by Capital Market - Live

Laurus Labs has fixed 31 October 2025 as the record date for the determining the eligibility of the Shareholders for Dividend.Powered by Capital Market - Live

Laurus Labs announced that the Board of Directors of the Company at its meeting held on 23 October 2025, inter alia, have recommended the interim dividend of Rs 0.8 per equity Share (i.e. 40%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Laurus Labs will hold a meeting of the Board of Directors of the Company on 23 October 2025.Powered by Capital Market - Live

Laurus Labs Ltd gained for a third straight session today. The stock is quoting at Rs 862.05, up 2.41% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.66% on the day, quoting at 24773.05. The Sensex is at 80791.81, up 0.65%. Laurus Labs Ltd has gained around 0.23% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has gained around 0.13% in last one month and is currently quoting at 21454.25, up 1.1% on the day. The volume in the stock stood at 11.98 lakh shares today, compared to the daily average of 17.33 lakh shares in last one month. The benchmark October futures contract for the stock is quoting at Rs 866.75, up 2.26% on the day. Laurus Labs Ltd is up 87.08% in last one year as compared to a 1.89% slide in NIFTY and a 6.42% slide in the Nifty Pharma index.The PE of the stock is 89.19 based on TTM earnings ending June 25.Powered by Capital Market - Live

Laurus Labs Ltd is up for a third straight session in a row. The stock is quoting at Rs 874.75, up 1.7% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.15% on the day, quoting at 24615.6. The Sensex is at 80252.95, up 0.12%. Laurus Labs Ltd has risen around 1.57% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has risen around 1.03% in last one month and is currently quoting at 21719.95, up 0.94% on the day. The volume in the stock stood at 7.54 lakh shares today, compared to the daily average of 15.93 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 876.65, up 1.29% on the day. Laurus Labs Ltd is up 83.93% in last one year as compared to a 2.31% drop in NIFTY and a 5.43% drop in the Nifty Pharma index.The PE of the stock is 91.1 based on TTM earnings ending June 25.Powered by Capital Market - Live

Gross margin improved to 59.4% in Q1 June 2025, up from 55.1% in Q1 June 2024. Profit before tax (PBT) stood at Rs 224 crore for Q1 June 2025, reflecting a 1,144% increase over Q1 June 2024. EBITDA was Rs 389 crore in Q1 June 2025, up 127% compared to Q1 June 2024. EBITDA margin rose to 24.8%, up from 14.3% in Q1 June 2024. In Q1 FY26, Laurus Labs' Contract Development and Manufacturing Operations (CDMO) revenue more than doubled year-on-year to Rs 522 crore, driven by a 130% increase in small molecules revenue, although the bio-segment saw a 33% decline. Revenue from the Generics division rose 12% to Rs 1,048 crore, with APIs dipping 4% but finished dosages (FDF) surging 50%. Additionally, ARV revenues advanced 17% to Rs 647 crore during the period under review. Dr. Satyanarayana Chava, founder & chief executive officer commented: We made healthy progress to start the year with increasing contributions from CDMO business and continued advancement of pipeline projects, supported by Generic FDF. We are moving ahead with strong focus on commercial execution realizing the full potential from promising pipeline opportunities, business development and rapidly enhancing scale and technology capabilities. We also commenced construction of various facilities across CDMO, Generics and FDF. Once complete, these facilities will fortify our ongoing commitment of being a high-quality development and manufacturing partner at scale including advanced therapies. We remain confident in our strategic direction and commitment as the source of sustainable value creation now and well into the future. V V Ravi Kumar, executive director & chief financial officer commented: We delivered a solid performance in Q1, in line with expectations. We are pleased to see sustained growth momentum fueled by increasing uptake in CDMO deliveries and healthy business fundamentals. The EBITDA margins improved substantially to 24.8%, supported by continuing operating leverage. Gross margins stood strong at 59.4% due to favorable CDMO mix and ongoing process improvement initiatives. We will continue to invest fully behind high value business opportunities to drive near and long-term growth and returns for our shareholders. Meanwhile, the Government of Andhra Pradesh has allotted 531.77 acres of land in IP Rambilli Phase-II, Anakapalli District, to the company for the establishment of Laurus Pharma Zone (LPZ), where it plans to set up manufacturing units for pharmaceutical products. Laurus Labs has earmarked an investment of Rs 5,630 crore for this project, which is expected to generate employment for 6,350 people in three phases over eight years. This land allotment marks a significant milestone, securing a crucial component for the company's future expansion plans. Laurus Labs is a research-driven pharmaceutical and biotechnology company. It develops and manufactures select Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF) across anti-retroviral, oncology, cardiovascular, and gastro therapeutics. It offers end-to-end CDMO services, supporting innovators from early-stage development to commercial production. Powered by Capital Market - Live

Laurus Labs Ltd gained for a third straight session today. The stock is quoting at Rs 893.5, up 6.65% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.37% on the day, quoting at 24744.75. The Sensex is at 81052.89, down 0.5%. Laurus Labs Ltd has risen around 23.27% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has risen around 3.26% in last one month and is currently quoting at 22662.7, up 0.42% on the day. The volume in the stock stood at 132.02 lakh shares today, compared to the daily average of 25.38 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 894.85, up 6.89% on the day. Laurus Labs Ltd is up 98.12% in last one year as compared to a 0.37% drop in NIFTY and a 4.99% drop in the Nifty Pharma index.The PE of the stock is 133.02 based on TTM earnings ending March 25.Powered by Capital Market - Live

Poonawalla Fincorp Ltd, Kajaria Ceramics Ltd, Aadhar Housing Finance Ltd, SBI Life Insurance Company Ltd are among the other stocks to see a surge in volumes on BSE today, 28 July 2025.Laurus Labs Ltd registered volume of 5.58 lakh shares by 10:46 IST on BSE, a 6.88 fold spurt over two-week average daily volume of 81093 shares. The stock rose 5.78% to Rs.886.45. Volumes stood at 1.44 lakh shares in the last session.Poonawalla Fincorp Ltd saw volume of 3.01 lakh shares by 10:46 IST on BSE, a 5.05 fold spurt over two-week average daily volume of 59535 shares. The stock increased 6.24% to Rs.439.30. Volumes stood at 1.15 lakh shares in the last session.Kajaria Ceramics Ltd witnessed volume of 12.48 lakh shares by 10:46 IST on BSE, a 4.66 times surge over two-week average daily volume of 2.68 lakh shares. The stock increased 1.05% to Rs.1,179.70. Volumes stood at 4.16 lakh shares in the last session.Aadhar Housing Finance Ltd registered volume of 4.11 lakh shares by 10:46 IST on BSE, a 4.19 fold spurt over two-week average daily volume of 98011 shares. The stock rose 4.53% to Rs.519.40. Volumes stood at 56797 shares in the last session.SBI Life Insurance Company Ltd recorded volume of 72077 shares by 10:46 IST on BSE, a 3.28 times surge over two-week average daily volume of 21965 shares. The stock gained 0.67% to Rs.1,845.15. Volumes stood at 64706 shares in the last session.Powered by Capital Market - Live